Physician profile
Wayne Brian Sida
NPI 1700886009
$2,214.20
in general payments reported to CMS, 2019-2025
23 companies · $540 in 2025
The $540 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $258 · 2021: $237 · 2022: $169 · 2023: $437 · 2024: $251 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,227.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $909.54 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Allergan, INC. | $316.25 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $309.68 | 2019-2021 | |
| Octapharma USA, INC. | $108.08 | 2023 | Panzyga |
| Livanova USA, INC. | $91.29 | 2021-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Emd Serono, INC. | $72.96 | 2019-2025 | |
| Cala Health, INC. | $50.34 | 2025 | Cala Kiq |
| Averitas Pharma INC. | $48.60 | 2025 | Qutenza |
| E.R. Squibb & Sons, L.L.C. | $29.76 | 2020 | |
| Abbott Laboratories | $27.55 | 2021-2022 | |
| Biogen, INC. | $27.03 | 2025 | Vumerity |
| Argenx US, INC. | $26.65 | 2024 | Vyvgart Hytrulo |
| Genzyme Corporation | $26.60 | 2025 | |
| Janssen Pharmaceuticals, INC | $21.44 | 2022 | |
| Mdd US Operations, LLC | $21.04 | 2024 | Gocovri |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $19.80 | 2024 | Rexulti |
| Ge Healthcare | $18.91 | 2020 | |
| Grifols USA, LLC | $16.30 | 2024 | Gamunex-C |
| Amgen INC. | $16.21 | 2025 | Uplizna |
| Catalyst Pharmaceuticals, INC. | $15.34 | 2023 | Fycompa |
| Sunovion Pharmaceuticals INC. | $14.30 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.17 | 2023 | Austedo Xr |
| Pfizer INC. | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Sida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.